PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|23|6|894-902

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.23, Iss.6, 2017-03, pp. : 894-902

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Peroxisome Proliferator-Activated Receptor-&ggr; (PPAR-&ggr;) Agonists on Glycemic Control, Lipid Profile and Cardiovascular Risk

By  

Current Molecular Pharmacology, Vol. 5, Iss. 2, 2012-01 ,pp. : 272-281

Bentham Science Publishers

Access to resources Recommend Favorite

PPAR-&ggr; Agonists in Polycystic Kidney Disease with Frequent Development of Cardiovascular Disorders

By  

Current Molecular Pharmacology, Vol. 5, Iss. 2, 2012-06 ,pp. : 292-300

Bentham Science Publishers

Access to resources Recommend Favorite

-adrenoceptor agonists increase cardiovascular risk

By  

Inpharma, Vol. 1, Iss. 1451, 2004-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

PPAR-β/δ agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home

By Billin Andrew N  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 10, 2008-10 ,pp. : 1465-1471

Informa Healthcare

Access to resources Recommend Favorite

Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis

By  

Current Pharmaceutical Design, Vol. 23, Iss. 7, 2017-04 ,pp. : 1119-1124

Bentham Science Publishers

Access to resources Recommend Favorite